Q3 2025 EPS Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Lifted by Zacks Research

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Zacks Research increased their Q3 2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Wednesday, October 9th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $0.19 per share for the quarter, up from their prior estimate of $0.18. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.52 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.78 EPS and Q3 2026 earnings at $0.32 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. The business had revenue of $241.96 million during the quarter, compared to analysts’ expectations of $235.95 million. ACADIA Pharmaceuticals had a net margin of 3.43% and a return on equity of 6.89%. The company’s quarterly revenue was up 46.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.01 earnings per share.

A number of other analysts also recently commented on ACAD. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 8th. Raymond James reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday. StockNews.com upgraded ACADIA Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 13th. Cantor Fitzgerald reduced their price target on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada lowered their price objective on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $25.56.

ACADIA Pharmaceuticals Trading Up 2.5 %

Shares of ACAD opened at $14.92 on Monday. The stock’s 50-day moving average price is $15.82 and its two-hundred day moving average price is $16.32. ACADIA Pharmaceuticals has a 1 year low of $14.31 and a 1 year high of $32.59. The stock has a market cap of $2.47 billion, a P/E ratio of -1,492.00, a price-to-earnings-growth ratio of 0.49 and a beta of 0.38.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Park Place Capital Corp purchased a new stake in shares of ACADIA Pharmaceuticals during the third quarter valued at about $25,000. Covestor Ltd lifted its position in shares of ACADIA Pharmaceuticals by 70.5% during the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 840 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at about $48,000. Stonepine Capital Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at about $81,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at about $111,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, COO Brendan Teehan sold 9,534 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $145,679.52. Following the sale, the chief operating officer now directly owns 52,177 shares in the company, valued at approximately $797,264.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, COO Brendan Teehan sold 9,534 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $145,679.52. Following the transaction, the chief operating officer now directly owns 52,177 shares in the company, valued at approximately $797,264.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Mark C. Schneyer sold 9,733 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $148,720.24. Following the completion of the transaction, the chief financial officer now owns 43,735 shares in the company, valued at approximately $668,270.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,014 shares of company stock worth $779,494 in the last 90 days. Insiders own 28.30% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.